BEST UNLIMITED TURBO LONG CERTIFICATE - EDWARDS LIFESCIENCES | Real-time Euronext Paris 08:39:14 2024-05-13 EDT | ||
| 6.39 EUR | -0.31% |
|
| Current month | +4.85% | ||
| 1 month | -12.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 6.39 | -0.31% | 20 |
| 24-05-10 | 6.48 | +1.09% | 43 |
| 24-05-09 | 6.41 | +4.40% | 50 |
| 24-05-08 | 6.14 | -2.07% | 56 |
| 24-05-07 | 6.27 | +2.45% | 66 |
Real-time Euronext Paris
Last update May 13, 2024 at 08:39 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Société Générale
|
| 395CS | |
| ISIN | DE000SU1DHN3 |
| Date issued | 2023-10-30 |
| Strike | 52.86 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 2.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.23 € |
|---|---|
| Lowest since issue | 2.07 € |
| Spread | 0.15 € |
| Spread % | 2.32% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
86.72
USD
Average target price
95.27
USD
Spread / Average Target
+9.86%
- Stock Market
- Certificates
- 395CS Certificat